JR

Jason Rhodes

Atlas Venture

Cambridge, Massachusetts

VC

Invests in

Stages:

Seed

  • Min Investment:

    $500,000.00

  • Max Investment:

    $5,000,000.00

  • Target Investment:

    $2,000,000.00

Skills

Venture Capital
Corporate Development
Alliances
Investments
Life Sciences
Biotechnology
Strategic Partnerships
Business Alliances
Strategy
Oncology
Mergers
Private Equity
Drug Discovery
Lifesciences
Technology Transfer
Pharmaceutical Industry
Commercialization
Business Development
Strategic Alliances
Product Development

Education

Investments

Accent Therapeutics

Series A

Total Funding: $180M

K36 Therapeutics

Series A

Total Funding: $100M

AAVantgarde Bio

Series A

Total Funding: $65M

Be Biopharma

Series A

Total Funding: $180M

Rectify Pharmaceuticals

Series A

Total Funding: $100M

Gemini Therapeutics

Seed

Total Funding: $140M

Generation Bio

Series A

Total Funding: $140M

Third Harmonic Bio

Series A

Total Funding: $50M

Disarm Therapeutics

Series A

Total Funding: $30M

Replimune Group

Series A

Total Funding: $85M

Raze Therapeutics

Series A

Total Funding: $24M

Work Experience

Atlas Venture

2014

  • Partner

    2014

Rectify Pharma

2020

  • Executive Chair (and founding CEO)

    2020

Generation Bio

2016

  • Chairman (and founding CEO)

    2016

    www.generationbio.com

Dyne Therapeutics

2017

  • Chairman (and founding CEO)

    2017

Berklee College of Music

2009 - 2022

  • Presidential Advisory Council, Member

    2009 - 2022

Disarm Therapeutics (acquired by Lilly in 2020)

2016 - 2020

  • Chairman (and founding CEO)

    2016 - 2020

Epizyme

2010 - 2014

  • President and CFO

    2010 - 2014

Alnylam

2007 - 2010

  • Vice President, Business Development

    2007 - 2010

    Alnylam is a biopharmaceutical company developing novel therapeutics based on RNAi. Led strategic collaborations with Takeda, GSK, Kyowa Hakko Kirin, Medtronic, Cubist and Roche, and spin out of Regulus (RGLS).

Fidelity Biosciences

2001 - 2007

  • Partner

    2001 - 2007

    Biotech venture capital arm of Fidelity Investments. Led investments in therapeutics companies including FoldRx, acquired by Pfizer.